Aptevo Therapeutics Inc. Deferred Income Tax Expense (Benefit)
Aptevo Therapeutics Inc. (APVO) reported Deferred Income Tax Expense (Benefit) of -$10.54 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-18.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2019-03-18
- Aptevo Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2017 was -$10.54M.
- Aptevo Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2016 was -$15.19M.
- Aptevo Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2015 was -$1.36M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2017-12-31 | -$10.54M 10-K · filed 2019-03-18 | |
| 2016-12-31 | -$15.19M 10-K · filed 2018-03-13 | -$15.31M 10-K · filed 2017-03-31 |
| 2015-12-31 | -$1.36M 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |